News

Elevation Oncology Highlights Upcoming H.C. Wainwright Conference

Elevation Oncology Highlights Upcoming H.C. Wainwright Conference

Elevation Oncology to Shine at Investment Conference

Elevation Oncology, Inc. (NASDAQ: ELEV) is set to highlight its innovative advancements in oncology at the prestigious H.C. Wainwright 26th Annual Global Investment Conference. This important event brings together key investors and industry leaders who are interested in groundbreaking healthcare solutions that tackle some of the most urgent challenges in the field.

Conference Details

Joseph J. Ferra, the Chief Executive Officer of Elevation Oncology, will engage in a fireside chat addressing vital topics related to the future of cancer treatment. This presentation is scheduled for an upcoming Tuesday at 11:30 am ET. Investors and stakeholders looking for insights can anticipate valuable discussions about Elevation’s cutting-edge therapies.

Event Accessibility

The event will be available through a live webcast, making it easy for those interested in Elevation Oncology’s initiatives to participate. Additionally, a replay will be accessible for anyone who cannot attend live, providing a great opportunity for information sharing and engagement.

Webcast Details

To watch the event, viewers can visit the Company's Investor Relations website, where the webcast will be hosted. Staying informed about these developments is essential for anyone following Elevation Oncology's progress in cancer therapy innovation.

Elevation Oncology's Mission and Focus

Elevation Oncology is dedicated to pioneering selective cancer therapies that meet patient needs across a range of solid tumors. The company is particularly focused on developing novel antibody-drug conjugates (ADCs) to address significant medical areas that are currently underserved.

Innovative Pipeline

The company is advancing a distinctive pipeline that targets clinically validated areas in oncology, specifically focusing on Claudin 18.2 and HER3, which are relevant in various cancers. The lead candidate, EO-3021, is gaining attention as it is designed to be a best-in-class ADC.

Current Trials and Future Prospects

EO-3021 is currently being evaluated in a Phase 1 trial involving patients diagnosed with advanced, unresectable, or metastatic solid tumors likely to express Claudin 18.2, including gastric and pancreatic cancers. Exciting developments are anticipated as the company prepares to announce a development candidate targeting HER3 in 2024.

Broader Impact of Elevation Oncology

With a mission focused on benefiting patients, Elevation Oncology is committed to transforming the landscape of oncology. The company’s innovative strategies have the potential to significantly improve treatment outcomes for patients facing some of the most challenging cancers.

Ongoing Commitment to Research

Research and development are at the heart of Elevation's operations. By continually investing in their ADC platform and committing to clinical validation, they remain leaders in oncology innovation. Elevation’s efforts aim not only to enhance medication efficacy but also to contribute significantly to the overall understanding and management of cancer treatment.

Engagement with the Community

Elevation Oncology's participation in conferences like the H.C. Wainwright event helps to boost its visibility. By engaging with investors, the company fosters essential partnerships for growth, shaping the future of oncology. For more information about Elevation and its advancements, visitors can explore their official website at www.ElevationOncology.com.

Investor and Media Contact Information

If you have inquiries related to investor relations or media requests, please contact Hannah Deresiewicz, EVP and Managing Director at Precision AQ, using the following details:

Phone: 212-362-1200
Email: [email protected]

Frequently Asked Questions

What is the main focus of Elevation Oncology?

Elevation Oncology is dedicated to developing selective cancer therapies that target various solid tumors, addressing significant unmet medical needs.

When will Joseph J. Ferra be speaking?

Joseph J. Ferra will be speaking during a fireside chat on Tuesday at 11:30 am ET at the H.C. Wainwright Conference.

How can I watch the presentation live?

The presentation will be available through a live webcast on the Company's Investor Relations website.

What is EO-3021?

EO-3021 is Elevation Oncology's lead ADC candidate aimed at Claudin 18.2, which is currently being evaluated in Phase 1 trials.

What is next for Elevation Oncology?

Elevation Oncology is planning to nominate a development candidate for a HER3-targeting ADC in 2024, further expanding their innovative pipeline.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 10

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 72

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 131

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 71

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 152

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading

Top 5 Most Recently Viewed Articles

ParagonX Holdings: Update on Company Transformation Plans

Updated Category News Views 146

ParagonX Holdings Shareholder Update ParagonX Holdings, Inc. (OTC:CAVR) recently shared insightful information regarding its transformation and strategic direction. The company is under the management of Caprino Management, LLC, which is actively assessing acquisition opportunities to bolster its growth. Divestitures and Debt Restructuring A significant step taken by...

Continue Reading
Applaud Receives Prestigious AI Award for Transforming HR

Updated Category News Views 300

Applaud Triumphs with Prestigious AI Award Applaud, a leading innovator in HR technology, has achieved significant recognition in the tech industry. The company’s generative-AI HR platform was awarded the flagship AI Award at a major international event. Applaud was selected among several finalists, showcasing its commitment to providing measurable value to employees...

Continue Reading
Empowering Stories: A Mother's Journey to a New Start

Updated Category News Views 257

Empowering Stories: A Mother's Journey to a New Start Anita's story is one of resilience. Faced with overwhelming challenges in her early life, she fought tirelessly to change her circumstances. Growing up without a family, she was married at a tender age to an older man, and for years, she juggled the responsibilities of motherhood while tending to her husband’s...

Continue Reading
First Capital REIT Declares Monthly Distribution for Investors

Updated Category News Views 176

First Capital REIT Announces Distribution for October 2025 First Capital REIT announces its cash distribution for October 2025, setting a notable precedent for its unitholders. The company has declared a distribution of $0.074167 per REIT unit, which translates to an annualized payout of $0.89 per unit. The payment is scheduled for November 17, 2025, to unitholders...

Continue Reading
Sidus Space and Other Major Stocks Experience Declines

Updated Category News Views 166

Stock Market Dynamics: Sidus Space and Others The U.S. stock market is seeing some fluctuations as futures showed little movement earlier today. Among these movements, Nasdaq 100 futures gently slipped by about 0.01%. In the midst of this, shares of Sidus Space, Inc. (NASDAQ: SIDU) are particularly noteworthy. Sidus Space's Price Adjustment Sidus Space recently made...

Continue Reading